PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse

Yang, Jing; Wu, Ning-Ni; Huang, Daixin; Luo, Yao‐Chang; Huang, Junzhen; He, Hai‐Yuan; Lu, Hailin; Song, Wenling

doi:10.1177/1010428317713492

Cited by 19 publications

(14 citation statements)

References 24 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, our finding confirmed an oncogenic role of PPFIA1 in tumour cell invasion where we found high PPFIA1 levels is significantly correlated with the development of distant metastasis in the liver. This result ties well with previous study, which showed PPFIA1 expression was significantly higher in liver metastatic tumours than in the primary tumours [24], and PPFIA1 overexpression enhanced cell spreading and cell migration [7]. Altogether, these findings suggesting a potential role for PPFIA1 expression in the invasive process within breast tumour cells.…”

Section: Discussionsupporting

confidence: 93%

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer

et al. 2020

View full text Add to dashboard Cite

Background: PPFIA1 is an important regulator of cell migration and invasion, regulating focal adhesion signalling and disassembly. PPFIA1 is frequently amplified in breast cancer, and recent functional studies indicate that PPFIA1 is an important promoter of migration and invasion in breast cancer. This study aims to evaluate the utility of PPFIA1 expression in the luminal breast cancer as a prognostic marker to predict the response to endocrine therapy. Methods: Large, well-characterised cohorts of primary luminal breast cancer patients with long-term follow-up was assessed for the clinical impact of PPFIA1 expression at the transcriptomic and proteomic levels. Prognostic significance of PPFIA1 and its relationship with clinical outcome and benefit of endocrine therapy were analysed. In addition, its association with other related-genes was analysed. Results: There was significant association between PPFIA1 expression and a member of the liprin family that involves in cell invasion (PPFIBPI), and the cell cycle regulator (CCND1), whereas a negative association was observed with the tumour suppressor gene (CD82). Patients with high PPFIA1 expression were associated with high risk of recurrence, distant metastasis and death from breast cancer (P < 0.05). Importantly, high PPFIA1 expression predicted relapse in a subset of patients who were subject to endocrine treatment alone, and was an independent prognostic marker of unfavourable outcome in these patients (P < 0.05). Conclusions: These findings support the proposed role for PPFIA1 as a regulator of cell migration in breast cancer and provides definitive evidence for the clinical utility of PPFIA1 expression in patients with luminal breast cancer. Most importantly, our data suggests that PPFIA1 might be a potential predictive marker for poor benefit from endocrine therapy.

show abstract

Section: Discussionsupporting

confidence: 93%

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 125 PPFIA1 (liprin-α1) expression can be significantly higher in the liver metastases than the primary tumors and serves as a potential poor prognostic indicator of increased metastatic relapse in ER + /N − (nodal negative) breast cancer group. 136 β-catenin-independent WNT signaling coincides with a poor prognosis in patients with breast cancer liver metastasis. 124 …”

Section: Liver Metastasismentioning

confidence: 99%

Organotropism: new insights into molecular mechanisms of breast cancer metastasis

et al. 2018

View full text Add to dashboard Cite

Metastasis accounts for 90% of breast cancer mortality. Despite the significant progress made over the past decade in cancer medicine our understanding of metastasis remains limited, therefore preventing and targeting metastasis is not yet possible. Breast cancer cells preferentially metastasize to specific organs, known as “organotropic metastasis”, which is regulated by subtypes of breast cancer, host organ microenvironment, and cancer cells-organ interactions. The cross-talk between cancer cells and host organs facilitates the formation of the premetastatic niche and is augmented by factors released from cancer cells prior to the cancer cells’ arrival at the host organ. Moreover, host microenvironment and specific organ structure influence metastatic niche formation and interactions between cancer cells and local resident cells, regulating the survival of cancer cells and formation of metastatic lesions. Understanding the molecular mechanisms of organotropic metastasis is essential for biomarker-based prediction and prognosis, development of innovative therapeutic strategy, and eventual improvement of patient outcomes. In this review, we summarize the molecular mechanisms of breast cancer organotropic metastasis by focusing on tumor cell molecular alterations, stemness features, and cross-talk with the host environment. In addition, we also update some new progresses on our understanding about genetic and epigenetic alterations, exosomes, microRNAs, circulating tumor cells and immune response in breast cancer organotropic metastasis.

show abstract

“…A study by Yang et al showed that the gene PPFIA1 is upregulated in those patients with liver metastases and is likely a poor prognostic factor for metastatic growth. 59 This report suggests potential for further research into this and other related genes that may drive metastatic growth within the liver. Additionally, determining whether survival postlocal therapy is associated with PPFIA1 mutation would possibly help in determining which patients are best for locoregional therapies.…”

Section: Breast Cancermentioning

confidence: 87%

Genomics and Interventional Oncology in Metastatic Liver Cancer

Case

Slovak

2020

Digestive Disease Interventions

View full text Add to dashboard Cite

This review aims to investigate the current literature on genetic and genomic biomarkers of locoregional interventions on metastatic liver metastases. A brief overview on the most common cancers that metastasize to the liver and the role locoregional therapies, such as ablation, chemoembolization, and radioembolization, play in their treatment will be presented. Review of the literature on the genetic, metabolic, and other molecular biomarkers and how they relate to posttreatment survival and outcomes will be discussed. Evaluation of how the existing data can better inform decisions regarding locoregional treatments in those patients with metastatic lesions of the liver will be completed. Personalized treatment paradigms in different types of metastatic cancer present significant opportunities for improved overall clinical outcomes. Optimizing patient selection for localized treatments is vital to improving outcomes and determining which biomarkers correlate with improved efficacy presents many avenues for future research.

show abstract

PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse

Cited by 19 publications

References 24 publications

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer

Organotropism: new insights into molecular mechanisms of breast cancer metastasis

Genomics and Interventional Oncology in Metastatic Liver Cancer

Contact Info

Product

Resources

About